


#6



DOCKET NO.: 201803US0DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: : GROUP ART UNIT:

NOBUYUKI ISE ET AL :

SERIAL NO.: 09/7⁶1,667 : EXAMINER:

FILED: JANUARY 18, 2001 :

FOR: TREPONEMA PALLIDUM FUSED ANTIGEN
AND ASSAY FOR ANTI-TREPONEMA
PALLIDUM ANTIBODIES USING THE SAME
FUSED ANTIGEN

RECEIVED
OCT 17 2001
TC 1700

RESPONSE TO NOTICE TO COMPLY WITH
REQUIREMENTS OF AUGUST 16, 2001

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:


RECEIVED
OCT 31 2001
TC 1700

The paper copy of the Sequence Listing in this application 09/761,667, is identical to the computer readable Sequence Listing filed in parent application Serial Number 08/773,106, filed December 26, 1996. In accordance with 37 CFR § 1.821 (e), please use the only computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the instant application. A paper copy of the Sequence Listing will be provided in a separately filed preliminary amendment

for incorporation into the present specification.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.




Norman F. Oblon
Attorney of Record
Registration No. 24,618

William E. Beaumont
Registration No. 30996



22850

Telephone: (703) 413-3000
Facsimile: (703) 413-2220



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/761,667	01/18/2001	Nobuyuki Ise	201803US

CONFIRMATION NO. 9063

22850

OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC
FOURTH FLOOR
1755 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VA 22202

FORMALITIES LETTER



OC000000006431970

RECEIVED

OCT 17 2001

TC 1700

Date Mailed: 08/16/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

RECEIVED
OCT 31 2001
TC 1700

*A copy of this notice **MUST** be returned with the reply.*




Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



1725



Docket No.: 201803US0DIV

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

RECEIVED

OCT 17 2001

TC 1700

ATTORNEYS AT LAW

NORMAN F. OBLON
(703) 413-3000
NOBLON@OBLON.COM

WILLIAM E. BEAUMONT
(703) 413-3000
WBEAUMONT@OBLON.COM

RE: Application Serial No.: 09/761,667
Applicant(s): NOBUYUKI ISE ET AL
Filing Date: JANUARY 18, 2001
For: TREPONEMA PALLADIUM FUSED ANTIGEN AND ASSAY FOR ANTI-
TREPONEMA PALLIDUM ANTIBODIES USING THE SAME FUSED ANTIGEN

SIR:

Attached hereto for filing are the following papers:

**RETURN NOTICE TO COMPLY
RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS OF AUGUST 16, 2001**

Our check in the amount of \$-0- is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 CFR 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon
Registration No. 24,618
Attorney of Record

William E. Beaumont
Registration No. 30,996



22850

RECEIVED
OCT 31 2001
TC 1700